Medication-info.com Search Menu

Zegfrovy (Sunvozertinib): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
150 mg, 200 mg
Active ingredient:

Patient information: uses, side effects, how to take - Zegfrovy

What is ZEGFROVY?

ZEGFROVY is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC):

  • that has spread to nearby tissues (locally advanced) or to other parts of the body (metastatic), and
  • has a certain abnormal epidermal growth factor receptor (EGFR) gene, and
  • whose disease has worsened while on or after chemotherapy that contains platinum.

Your healthcare provider will perform a test to make sure that ZEGFROVY is right for you.

It is not known if ZEGFROVY is safe and effective in children.

Before taking ZEGFROVY, tell your healthcare provider about all of your medical conditions, including if you:

  • have a history of eye or vision problems.
  • are pregnant or plan to become pregnant. ZEGFROVY can harm your unborn baby.

    Females who are able to become pregnant:

    • Your healthcare provider should do a pregnancy test before you start treatment with ZEGFROVY.
    • You should use an effective form of non-hormonal birth control (contraception) during treatment with ZEGFROVY and for 2 weeks after your last dose of ZEGFROVY.
    • Talk to your healthcare provider about birth control methods that might be right for you during this time.
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZEGFROVY.

    Males who have female partners who are able to become pregnant:

    • You should use effective birth control (contraception) during treatment with ZEGFROVY and for 2 weeks after your last dose of ZEGFROVY.
  • are breastfeeding or plan to breastfeed. It is not known if ZEGFROVY passes into your breast milk. Do not breastfeed during treatment with ZEGFROVY and for 2 weeks after your last dose of ZEGFROVY. Talk to your healthcare provider about the best way to feed your baby during treatment with ZEGROVY.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ZEGFROVY may affect the way other medicines work and other medicines may affect how ZEGFROVY works.

How should I take ZEGFROVY?

  • Take ZEGFROVY exactly as your healthcare provider tells you.
  • Do not change your dose or stop taking ZEGFROVY unless your healthcare provider tells you to.
  • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with ZEGFROVY if you develop certain side effects.
  • Take your prescribed dose of ZEGFROVY 1 time a day at the same time each day.
  • Take ZEGFROVY with food.
  • Swallow ZEGFROVY tablets whole. Do not split, crush, chew, or dissolve the tablets.
  • If you miss a dose of ZEGFROVY, take it as soon as you remember within 12 hours. If it has been more than 12 hours, skip the missed dose and take your next dose at your regularly scheduled time.
  • If you vomit after taking a dose of ZEGFROVY, do not take an extra dose. Take your next dose at your regularly scheduled time.

What are the possible side effects of ZEGFROVY?

ZEGFROVY may cause serious side effects, including:

  • Lung problems. ZEGFROVY can cause lung problems that can be severe and life-threatening. Symptoms may be similar to those from lung cancer. Tell your healthcare provider right away if you develop new or worsening symptoms of lung problems during treatment with ZEGFROVY, including shortness of breath or trouble breathing, cough, or fever.
  • Stomach and intestinal (gastrointestinal) problems. ZEGFROVY can cause stomach and intestinal problems that can be severe, including diarrhea, nausea, and vomiting. Tell your healthcare provider right away if you get any of these symptoms during treatment with ZEGFROVY. Your healthcare provider may prescribe medicines as needed, or recommend drinking fluids or other treatments, to help treat your symptoms.
  • Skin problems. ZEGFROVY can cause severe skin rashes. Use alcohol-free (such as isopropanol-free or ethanol-free) moisturizing cream during treatment with ZEGFROVY. Avoid use of irritating skin products, such as skin products containing retinol or retinoic acid, and benzoyl peroxide. Tell your healthcare provider right away if you develop any skin reactions, including small, raised skin bumps that look like acne or itchy skin.
  • Eye problems. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you develop new or worsening eye problems during treatment with ZEGFROVY. You should not use contact lenses until your eye symptoms are checked by a healthcare provider and for at least 1 week after your eye symptoms have resolved. Tell your healthcare provider right away if you develop any new or worsening symptoms of eye problems, including:
  • eye pain
  • eye redness
  • light sensitivity
  • feeling like something is in your eyes
  • increased tears
  • discharge from your eyes
  • eye irritation
  • dry eyes
  • eye crusting
  • blurred vision
  • loss of vision
  • vision problems

The most common side effects of ZEGFROVY include:

  • diarrhea
  • rash
  • decreased appetite
  • mouth sores
  • feeling very tired
  • nausea
  • infected skin around the nail
  • vomiting
  • constipation
  • muscle or joint pain
  • itchy skin
  • dry skin
  • urinary tract infection
  • stomach-area pain
  • decreased weight

The most common severe abnormal lab test results with ZEGFROVY include:

  • decreased white blood cell and red blood cell counts
  • increased pancreas enzyme levels
  • increased creatine kinase levels
  • decreased potassium and salt (sodium) levels
  • increase liver enzyme levels
  • increased magnesium levels

ZEGFROVY may affect fertility in females and males, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of ZEGFROVY.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store ZEGFROVY?

  • Store ZEGFROVY at room temperature between 68°F to 77°F (20°C to 25°C).

Keep ZEGFROVY and all medicines out of the reach of children.

General information about the safe and effective use of ZEGFROVY.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ZEGFROVY for a condition for which it was not prescribed. Do not give ZEGFROVY to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about ZEGFROVY that is written for health professionals.

What are the ingredients in ZEGFROVY?

Active ingredient: sunvozertinib

Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Tablet coating contains: hypromellose 2910, iron oxide yellow, titanium dioxide, and triacetin.

Manufactured for: Dizal Pharmaceutical Co., Ltd., Shanghai, 201203, China

Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850

ZEGFROVY is a trademark of the AstraZeneca group of companies.

©AstraZeneca 2026

DIZAL™ and the DIZAL Logo are trademarks of Dizal Pharmaceutical Co., Ltd.

©2025 Dizal Pharmaceutical Co., Ltd. All rights reserved.

For more information, call +1-855-482-0653.

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: NDA 219839 · View the label on DailyMed

Revision date stated in the text: August 2026

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Zegfrovy

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Active ingredient Sunvozertinib
Dosage form Tablet, film coated
Route Oral
Marketing status listed in the FDA NDC Directory
Company (applicant) DIZAL
FDA approval NDA 219839New Drug Application (NDA) Approved July 2, 2025
Reference listed drug This is the reference listed drug (RLD) that generics are compared with.
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
150 mg – 30 in 1 bottle / 1 in 1 carton
200 mg – 30 in 1 bottle / 1 in 1 carton

Source: FDA drug labeling via NLM DailyMed, data as of November 11, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.